Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Frederic Newman

Gastroenterology Pensacola, FL Medical Doctor

NPI 1568443299 CMS profile 343802

4531 N Davis Hwy, Pensacola, FL 32503

Open in the dashboard

General payments

$6,337

232 records reported · program years 2019–2025

Research payments

$19,062

Paid to them · 12 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,907,720 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Frederic Newman of Pensacola, FL is reported in the CMS Open Payments database as having received $6,337 across 232 general payments and $19,062 in research payments paid to them. Separately, studies naming them as principal investigator received $1,907,720 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 90th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $308 17
2025 Research $1,958 2
2024 General $501 28
2023 General $2,722 69
2022 General $900 33
2021 General $834 41
2021 Research $6,627 5
2020 General $509 21
2020 Research $6,474 2
2019 General $563 23
2019 Research $4,003 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Frederic Newman
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Frederic Newman were reported at $308. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Frederic Newman Gastroenterology median Middle half National median
2019 $563 $417 $126–$1,100 $163
2020 $509 $224 $74–$624 $114
2021 $834 $352 $106–$1,054 $132
2022 $900 $448 $129–$1,270 $149
2023 $2,722 $533 $150–$1,390 $160
2024 $501 $605 $160–$1,606 $164
2025 $308 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Apollo Endosurgery US Inc $1,618 6 payments
  2. AbbVie, Inc. $1,585 73 payments
  3. Janssen Biotech, Inc. $674 47 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $641 32 payments
  5. E.R. Squibb & Sons, L.L.C. $228 2 payments
  6. Celgene Corporation $176 10 payments
  7. Gilead Sciences, Inc. $128 6 payments
  8. Ironwood Pharmaceuticals, Inc $121 8 payments
  9. Covidien LP $89 1 payment
  10. Boston Scientific Corporation $86 1 payment
  11. Other $992 46 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,801 229 payments
  2. Travel and Lodging $1,469 2 payments
  3. Education $67 1 payment
Products named General payments · program years 2019–2025
  1. OverStitch Endoscopic Suturing System $1,595 5 payments
  2. STELARA $672 44 payments
  3. ENTYVIO $524 25 payments
  4. ZEPOSIA $372 10 payments
  5. HUMIRA $365 14 payments
  6. RINVOQ $358 18 payments
  7. SKYRIZI $339 17 payments
  8. LINZESS $317 21 payments
  9. MAVYRET $254 9 payments
  10. CREON $253 15 payments
  11. Other $1,781 88 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $19,062 12 payments

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

794

Median for Gastroenterology: 569

Drug cost

$163,888

Median for Gastroenterology: $104,976

Branded share of claims

34.6%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 81 $80,356
Creon Lipase/Protease/Amylase Brand 11 $46,491
Movantik Naloxegol Oxalate Brand 20 $9,573
Mesalamine Er Mesalamine Brand 18 $5,078
Sutab Sod Sulf/Pot Chloride/Mag Sulf Brand 20 $3,269
Budesonide Dr Budesonide Brand 21 $2,790
Pantoprazole Sodium Generic 223 $2,593
Ursodiol Generic 17 $2,421
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 12 $2,027
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 28 $1,790

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 67 billing codes

Paid by Medicare

$240,757

Of which drugs: $134,839

Medicare patients

608

Average age 73

Services billed

8,190

322 women, 286 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Ischemic heart disease 36%
Diabetes 34%
Chronic kidney disease 34%
Depression 28%
Atrial fibrillation 25%
COPD 25%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, vedolizumab, 1 mg J3380 Office 14 4,500 $78,641
Injection, infliximab, excludes biosimilar, 10 mg J1745 Office 22 1,970 $49,254

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $64
$64 — 4,500
TREMFYA
  • Janssen Biotech, Inc. $54
$54 — —
SKYRIZI
  • AbbVie, Inc. $53
$53 — —
RINVOQ
  • AbbVie, Inc. $50
$50 — —
LINZESS
  • AbbVie, Inc. $44
$45 81 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

244 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record